CurrentMolina HealthcarePolicy M2057

Diagnosis of Vaginitis

Defines coverage and limitations for laboratory and point-of-care diagnostic tests used to evaluate symptomatic vaginitis (BV, VVC, trichomoniasis) including microscopy, pH/amine tests, DNA hybridization probes, NAAT/PCR, culture, and multianalyte panels.

Policy Summary

PayerMolina Healthcare

PolicyDiagnosis of Vaginitis

Policy CodePolicy M2057

Change TypeRevisions and coding updates (clarificationsCPT additions/removals)

Effective Date

Next Review Date

Key ActionDocument clinical signs/symptoms of vaginitis before ordering multiplex NAAT panels and verify member benefits prior to testing.

SourceLink

POLICY UPDATE CHANGES

Revision Date 07/01/2025 listed in header.

Added sialidase activity to CC1 as an appropriate diagnostic tool and clarified CC1 wording to include testing of pH, amines, sialidase activity, saline wet mount, KOH wet mount, and microscopic examination.

Added CPT code 81515 to applicable procedure codes (effective 2025-01-01).

Added CPT code 0505U to applicable procedure codes (effective 2024-10-01).

Removed CPT code 0352U from applicable procedure codes (effective 2025-01-01).

Literature review updated background, guidelines, recommendations, and references but did not necessitate modifications to coverage criteria beyond the clarifications noted.

7Specific covered test categories listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Summary

This policy covers diagnostic testing for vaginitis, specifically evaluation of bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis using office and laboratory methods including pH/amine testing, microscopy (saline and KOH wet mounts), culture, DNA hybridization probes, nucleic acid amplification testing (NAAT/PCR), and multiplex panels. The scope emphasizes use in individuals presenting with signs and symptoms of vaginitis and defines which methods meet coverage criteria and which do not. Coverage stance: mixed — some molecular and multiplex assays are covered when used for symptomatic patients while other tests or indications are not covered. Providers are reminded that coverage is intended primarily for symptomatic testing and that clinical documentation of signs/symptoms should accompany orders for NAAT/multiplex testing.

Key thresholds

Vaginal pH interpretationNormal premenopausal pH 4.0-4.5; pH >4.5 suggests BV; pH 5-6 suggests trichomoniasis; premenarchal/postmenopausal normal pH ≥4.7

Affirm VP III detection threshold>5 x 10^5 CFU of G. vaginalis per mL of vaginal fluid (detects high concentrations of G. vaginalis)

Medical-Necessity Criteria

Covered (MEETS COVERAGE CRITERIA)

For individuals with signs and symptoms of vaginitis, the following tests meet coverage criteria:

Office/point-of-care and microscopy: Testing of pH, testing for the presence of amines, measurement of sialidase activity, saline wet mount, potassium hydroxide (KOH) wet mount, and microscopic examination of vaginal fluids
Point-of-care and office microscopy methods are included
Direct probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm™ VPIII)
Vaginal culture for Candida: Vaginal cultures for Candida species when wet-mount preparations are negative and vaginal pH test is normal, for diagnosis of vulvovaginal candidiasis
NAAT/PCR for Trichomonas: Nucleic acid amplification testing (NAAT) or PCR-based identification of Trichomonas vaginalis
Trichomonas screening for risk factors:

Coverage Criteria (selected clarifications and CC1 example)

Covered when ALL of the following are met:

Symptomatic requirement: Individual has signs and symptoms of vaginitis
Symptomatic testing only; multiplex tests not intended for asymptomatic screening or test-of-cure per guidelines
Diagnostic methods included in CC1: Testing includes one or more of: pH testing, testing for presence of amines, measurement of sialidase activity, saline wet mount, potassium hydroxide (KOH) wet mount, and microscopic examination of vaginal fluids
Sialidase activity was added to CC1 as an appropriate diagnostic tool
NAAT intended use: Use of nucleic acid amplification testing (NAAT) is supported for diagnosis of trichomoniasis and for multiplex panels for vaginitis entities per guideline recommendations
NAATs and FDA-cleared multiplex panels are intended for symptomatic women

Not Covered (Does Not Meet Coverage Criteria)

Not Covered (DOES NOT MEET COVERAGE CRITERIA)

The following tests do not meet coverage criteria due to lack of sufficient published evidence:

Rapid enzyme immunoassay for Trichomonas: Rapid identification of Trichomonas by enzyme immunoassay
Molecular panels for vaginal flora/infertility: Testing for microorganisms involved in vaginal flora imbalance and/or infertility using molecular-based panel testing
Other tests not addressed: All other tests for vaginitis not addressed above

Non-coverage determinations are based on a lack of sufficient published scientific literature supporting clinical benefit for certain tests (for example, rapid Trichomonas enzyme immunoassays and molecular panels intended for indications such as vaginal flora imbalance/infertility), and the policy cites an evidence gap in available published studies as the rationale for those exclusions.

Coding

Applicable CPT/HCPCS procedure codesmixed

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis (Aptima® BV Assay, Hologic, Inc.)
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, BVAB-2, and Lactobacillus species, includes separate detection of Trichomonas vaginalis and/or Candida species
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and BVAB-2, utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis (BD MAX™ Vaginal Panel). Note: CPT 81515 was added effective 1/1/2025 per revision history.
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique (Bridge Women's Health Infectious Disease Detection Test)
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism (NxGen MDx LLC)
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens

Primary covered proprietary/multiplex vaginal panel CPT codesCPTCovered

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species (Aptima® BV Assay, Hologic, Inc.)
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, BVAB-2, and Lactobacillus species; includes separate detection of Trichomonas vaginalis and/or Candida species
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and BVAB-2 (BD MAX™ Vaginal Panel). CPT 81515 added effective 1/1/2025 per revision history.
0330U	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique (Bridge Women's Health Infectious Disease Detection Test)
0505U	Infectious disease (vaginal infection), identification of 32 pathogenic organisms, swab, real-time PCR, reported as positive or negative for each organism (NxGen MDx LLC)

Other covered laboratory and microscopy CPT/HCPCS codesmixedCovered

82120	Amines, vaginal fluid, qualitative
83986	pH; body fluid, not otherwise specified
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed
87210	Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps)
87480	Infectious agent detection by nucleic acid (DNA or RNA); Candida species, direct probe technique
87481	Candida species, amplified probe technique
87482	Candida species, quantification
87510	Gardnerella vaginalis, direct probe technique
87511	Gardnerella vaginalis, amplified probe technique
87512	Gardnerella vaginalis, quantification

1–10 of 20

1/2

Provider Actions

Documentation Required

Symptomatic requirement

Document signs and symptoms of vaginitis (e.g., discharge, odor, itching, burning, irritation) in the medical record before ordering diagnostic testing. Clinical presentation should guide initial office testing (pH, amine/whiff test, saline/KOH wet mount, microscopy) and selection of further laboratory tests.

Document specific signs/symptoms and pelvic exam findings in the chart at time of testing

Documentation Required

Symptom documentation required

A documented clinical presentation consistent with vaginitis is required prior to ordering multiplex NAAT panels that test for multiple causes (e.g., BV, VVC, trichomoniasis). Ensure office evaluation findings (symptoms, pH, wet mount results) are recorded to support the medical necessity of multiplex molecular testing.

Record pH and wet-mount findings when available
Note rationale for ordering a multiplex NAAT panel in the encounter note

Background and Evidence

Vaginitis is a clinical syndrome most commonly caused by BV, VVC, and Trichomonas vaginalis and is diagnosed using a combination of symptoms, physical exam, and laboratory or point-of-care tests. Initial evaluation typically includes measurement of vaginal pH, amine ('whiff') testing, and microscopic examination (saline and KOH wet mounts) to identify clue cells, motile trichomonads, or yeast forms. Traditional microscopy and Amsel/Nugent criteria remain important rapid diagnostic approaches but have variable sensitivity. Molecular assays (NAAT/PCR/TMA) generally demonstrate higher sensitivity and specificity than microscopy or culture for many targets, provide improved detection of coinfections, and have become accepted diagnostic options for symptomatic women — for example, NAATs are the preferred standard for Trichomonas and multiple validated NAAT-based panels (Aptima BV/CV/TV, BD MAX Vaginal Panel, and others) show higher diagnostic performance compared with clinician assessment or point-of-care tests. However, molecular methods may detect organism colonization in asymptomatic individuals (notably PCR detection of Candida), so their use is recommended primarily in symptomatic patients.

Evidence item	Summary/performance
Aptima performance	Multicenter prospective study (n=1,519) reported Aptima BV sensitivity 95.0% and specificity 89.6% for BV; Aptima CV/TV: Candida group sensitivity 91.7% and specificity 94.9% (C. glabrata 84.7% sensitivity, 99.1% specificity); T. vaginalis sensitivity 96.5% and specificity 94.1% (Schwebke et al., clinical validation). FDA approved Aptima BV and CV/TV in 2019.
BD MAX performance	BD MAX Vaginal Panel reported study ranges: sensitivity for BV 94.4% and specificity 79% in one evaluation; overall reported sensitivities 86.4%–94.4% and specificities 79%–86.0% across studies. BD MAX received automatic FDA class III designation (2016) with subsequent 510(k) activity; CPT code 81515 assigned for BD MAX Vaginal Panel.
OSOM BVBlue	Point-of-care chromogenic test detecting elevated sialidase activity. Manufacturer reports 92.8% sensitivity and 98% specificity versus Gram stain; published studies report sensitivity 88%–94% and specificity 91%–97% compared with Gram stain/Amsel criteria with rapid ~10 minute read time.
Guideline consensus	CDC, ACOG, IDSA and other societies recommend use of pH, KOH/whiff, microscopic exam and note NAATs are recommended for trichomoniasis and are useful for BV in symptomatic women; multiplex NAATs demonstrate higher sensitivity, better detection of coinfections, and should be used in symptomatic patients only. ACOG endorses Amsel/Nugent for BV; IDSA and CDC note FDA-cleared multiplex NAATs (Aptima, BD MAX, Xpert MVP) and recommend their use in symptomatic women.
FDA approvals	FDA approved Aptima BV assay May 23, 2019. BD MAX Vaginal Panel received automatic class III designation (Oct 28, 2016) with subsequent 510(k) actions and labeling modifications; multiple multiplex vaginal NAATs are FDA-cleared (e.g., BD MAX and Aptima) while others are LDTs.

Definitions

BVBacterial vaginosis

VVCVulvovaginal candidiasis

NAATNucleic acid amplification testing (includes PCR and TMA) used to detect pathogens such as Trichomonas, Candida, and BV-associated bacteria

Revision History

07/01/2025revisionLatest

Policy reviewed and updated: background, guidelines, recommendations, and references updated; wording clarifications made to CC2, CC3, CC4, CC7, and CC8; sialidase activity added to CC1 and former standalone CC4 (measurement of sialidase activity) removed.

12/04/2024coding_modification

Off-cycle coding modification: CPT code 81515 added to applicable procedure codes effective 01/01/2025; CPT code 0352U removed effective 01/01/2025.

09/04/2024

Policy Summary

PayerMolina Healthcare

PolicyDiagnosis of Vaginitis

Policy CodePolicy M2057

Change TypeRevisions and coding updates (clarificationsCPT additions/removals)

Effective Date

Next Review Date

Key ActionDocument clinical signs/symptoms of vaginitis before ordering multiplex NAAT panels and verify member benefits prior to testing.

SourceLink

On This Page

Billing Rule

Use appropriate CPT/HCPCS code

Use the appropriate CPT/HCPCS code for molecular and other diagnostic tests. Codes and code descriptions should reflect the method and scope of testing performed. Be aware of coding updates and effective dates when selecting codes for claims submission.

81515 — Multiplex PCR/NAAT panels for infectious agents (effective dates per policy changes list)
0505U — Specific molecular test code (effective dates per policy changes list)
0352U — Specific molecular test code (effective dates per policy changes list)

Billing Rule

Microscopy and office tests as standard

Microscopy, vaginal pH measurement, amine (whiff) testing, saline and KOH wet-mount preparations are supported diagnostic methods when signs or symptoms of vaginitis are present. These office-based tests are appropriate initial evaluations and should be performed or documented when clinically available.

Supported office tests: vaginal pH, amine/whiff test, saline wet mount, KOH wet mount, microscopic examination

Documentation Required

Use of culture and PCR for Candida

Obtain vaginal culture and/or PCR-based testing for Candida species when clinical presentation suggests complicated or recurrent vulvovaginal candidiasis (VVC) or when initial office tests are negative but symptoms persist. Cultures can help identify non-albicans species that may influence antifungal selection.

Consider culture or PCR for Candida in recurrent, refractory, or complicated VVC to identify non-albicans species

Note

FDA-cleared vs LDT awareness

Be aware of the distinction between FDA-cleared tests and laboratory-developed tests (LDTs). LDTs are performed by clinical laboratories and are regulated under CLIA as high-complexity tests; they may be used clinically but differ from FDA-cleared commercial assays in regulatory pathway and validation. Document the test type when relevant to coverage determinations.

LDTs = CLIA-regulated high-complexity tests performed/validated by laboratories
FDA-cleared tests follow the FDA clearance pathway and may have different coverage or coding considerations
Document the specific test and whether it is FDA-cleared or an LDT in the medical record when relevant